BioSpace News Archive

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that it will present new studies on its TGF- β program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.

CalciMedica Inc., the CRAC channel company, announced the publication of a research paper describing how bile acid- and ethanol-mediated activation of Orai1 damages pancreatic ductal cells in AP.

A new peer review paper affirms that CooperVision® MiSight® 1 day contact lenses provide myopia control for nearly all children.†1 In the longest-running soft contact lens study among children, 90% of myopic eyes responded† to MiSight® 1 day wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.

Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced an in-person poster presentation will be given at the American Academy of Cancer Research (AACR) on its lead candidate, PT-112, and how it selectively induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 17, 2022 to report financial results for the year ended December 31, 2021 and discuss recent corporate highlights.

Exscientia and the University of Oxford Target Discovery Institute announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it will participate in an upcoming virtual investor conference.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced fourth quarter and year-end 2021 financial results and provided an update on the cytisinicline clinical development program.

PolarityTE, Inc. announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.

Suneva Medical, Inc., an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that it has appointed Michael Brower as its Chief Financial Officer.